Compositions and methods for treating and preventing neointimal stenosis
US9782522B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 5, 2016 |
| Grant date | Oct 10, 2017 |
| Priority date | — |
| Expiry date | Jul 5, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2300/624
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.